Race Oncology Limited (ASX: RAC) has reported a pivotal mechanistic discovery: its lead molecule (E,E)-bisantrene (RCDS1) primarily exerts anticancer activity by binding and stabilising G-quadruplex (G4) structures in DNA and RNA—not via an anthracycline-like pathway. The company positions this as a step-change for clinical strategy, biomarker development, and partnering.